Will AstraZeneca Q1 results bring positive surprise?
Roland Magnusson/iStock Editorial via Getty Images
- AstraZeneca (NASDAQ:AZN) is scheduled to announce Q1 earnings results on Thursday, April 27th, before market open.
- The consensus EPS Estimate is $0.82 (-56.6% Y/Y) and the consensus Revenue Estimate is $10.61B (-6.8% Y/Y).
- Over the last 2 years, AZN has beaten EPS estimates 88% of the time and has beaten revenue estimates 88% of the time.
- Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 3 downward.
- The British pharma giant's stock rose +4.75% on Feb. 9 following its Q4 results. Q4 saw a decline in sales of COVID vaccine Vaxzevria, but there was strong growth in Oncology, CVRM and Rare Disease segments.
- Product/Pipeline updates:
- AstraZeneca and Sanofi's RSV preventing therapy Beyfortus was approved in Canada for use in newborns.
- Rare disease drug Ultomiris inched ahead on the path to get an expanded approval in the EU.
- A combination treatment of Imfinzi and Lynparza improved progression-free survival in patients with a type of ovarian cancer in a phase 3 trial.
